Literature DB >> 21596817

Panitumumab (vectibix).

J J Gemmete1, S K Mukherji.   

Abstract

Panitumumab (Vectibix), is a human monoclonal antibody EGFR antagonist indicated as a single agent for the treatment of metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. This article will present the mechanism of action as well as the clinical role for this monoclonal antibody.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21596817      PMCID： PMC8013163          DOI： 10.3174/ajnr.A2601

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN： 0195-6108            Impact factor:   3.825


  9 in total

1.  Panitumumab.

Authors:  Eline A Dubois; Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

Review 2.  Spotlight on panitumumab in metastatic colorectal cancer.

Authors:  Gillian M Keating
Journal:  BioDrugs       Date:  2010-08-01       Impact factor: 5.807

Review 3.  Panitumumab: a review of its use in metastatic colorectal cancer.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2010-05-28       Impact factor: 9.546

Review 4.  Epidermal growth factor receptor as a therapeutic target in colorectal cancer.

Authors:  Roger B Cohen
Journal:  Clin Colorectal Cancer       Date:  2003-02       Impact factor: 4.481

Review 5.  Targeted therapies: a new generation of cancer treatments.

Authors:  David E Gerber
Journal:  Am Fam Physician       Date:  2008-02-01       Impact factor: 3.292

Review 6.  Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.

Authors:  E Martinelli; R De Palma; M Orditura; F De Vita; F Ciardiello
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

7.  Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer.

Authors:  Rossana Berardi; Azzurra Onofri; Mirco Pistelli; Elena Maccaroni; Mario Scartozzi; Chiara Pierantoni; Stefano Cascinu
Journal:  Core Evid       Date:  2010-10-21

8.  Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab.

Authors:  George P Kim; Axel Grothey
Journal:  Biologics       Date:  2008-06

9.  Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab.

Authors:  Daanish Hoda; George R Simon; Christopher R Garrett
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423
  9 in total
  9 in total

1.  Cellular and molecular properties of (90)Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro.

Authors:  M Saki; M Toulany; W Sihver; M Zenker; J-M Heldt; B Mosch; H-J Pietzsch; M Baumann; J Steinbach; H P Rodemann
Journal:  Strahlenther Onkol       Date:  2012-08-10       Impact factor: 3.621

2.  Posterior reversible encephalopathy syndrome with colitis in a patient treated with panitumumab.

Authors:  Céline Blaye; Xavier Buy; Marine Gross-Goupil; Didier Vincent; Claire Jamet; Paul Sargos; Stéphane Culine; Guilhem Roubaud
Journal:  Ther Adv Drug Saf       Date:  2017-01-16

Review 3.  Anticancer therapy and lung injury: molecular mechanisms.

Authors:  Li Li; Henry Mok; Pavan Jhaveri; Mark D Bonnen; Andrew G Sikora; N Tony Eissa; Ritsuko U Komaki; Yohannes T Ghebre
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-23       Impact factor: 4.512

Review 4.  Oxidative Stress in Cancer Cell Metabolism.

Authors:  Saniya Arfin; Niraj Kumar Jha; Saurabh Kumar Jha; Kavindra Kumar Kesari; Janne Ruokolainen; Shubhadeep Roychoudhury; Brijesh Rathi; Dhruv Kumar
Journal:  Antioxidants (Basel)       Date:  2021-04-22

Review 5.  Recent developments in receptor tyrosine kinases targeted anticancer therapy.

Authors:  Samir H Raval; Ratn D Singh; Dilip V Joshi; Hitesh B Patel; Shailesh K Mody
Journal:  Vet World       Date:  2016-01-29

6.  Nanocell targeting using engineered bispecific antibodies.

Authors:  Karin Taylor; Christopher B Howard; Martina L Jones; Ilya Sedliarou; Jennifer MacDiarmid; Himanshu Brahmbhatt; Trent P Munro; Stephen M Mahler
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 7.  Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers.

Authors:  Jinfeng Yu; Tong Fang; Chengyu Yun; Xue Liu; Xiaoqing Cai
Journal:  Front Mol Biosci       Date:  2022-02-28

8.  Management of dermatologic toxicities associated with monoclonal antibody epidermal growth factor receptor inhibitors: A case review.

Authors:  Christian Leporini; Francesca Saullo; Gianfranco Filippelli; Antonio Sorrentino; Maria Lucia; Gino Perri; Gaetana La Gattuta; Stefania Infusino; Rosa Toscano; Gianluca Dima; Virginia Olivito; Laura Paletta; Ugo Bottoni; Giovambattista De Sarro
Journal:  J Pharmacol Pharmacother       Date:  2013-12

Review 9.  How to select IgG subclasses in developing anti-tumor therapeutic antibodies.

Authors:  Jifeng Yu; Yongping Song; Wenzhi Tian
Journal:  J Hematol Oncol       Date:  2020-05-05       Impact factor: 17.388
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.